Thursday 24th September 2009 - AusBiotech has announced the Hon John Brumby, Premier of Victoria will officially open the inaugural Australasian Life Science Investment Summit, a one-day event designed to support and stimulate investment in Australia’s biotechnology research and development.
The event, which precedes AusBiotech 2009, the premier biotechnology conference for the Asia Pacific region, will give 40 Australian companies access to global life science investors by providing the opportunity to present to a range of national and international investors about their innovations.
The Summit has attracted national and international investors including angel investors, venture capitalists, fund managers, investment bankers and representatives of superannuation funds. Venture capital arms of the major pharmaceutical and biotechnology companies from Australia, the Asia Pacific region, North America and Europe will also be attending.
Presenting companies will be a mix of listed companies in late-stage development, private companies with identified product/opportunities and early-stage commercialisation companies from research institutes and universities and include: CSL; Cochlear; ChemGenex; Starpharma; Biota Holdings; ResMed and Pharmaxis.
International investors confirmed include: ABN Ambro Morgans, Blueprint, CM Capital Investments, Baillieu Stockbroking, GBS Venture Partners, GlaxoSmithKline, Eli Lilly; 5AM Ventures; BioTech Healthcare Partners; SMH Capital; Amgen and Bailard.
For additional event information and a full list of confirmed attendees visit the Summit website at: http://www.ausbiotech2009.com.au/alsis/
The event, which precedes AusBiotech 2009, the premier biotechnology conference for the Asia Pacific region, will give 40 Australian companies access to global life science investors by providing the opportunity to present to a range of national and international investors about their innovations.
The Summit has attracted national and international investors including angel investors, venture capitalists, fund managers, investment bankers and representatives of superannuation funds. Venture capital arms of the major pharmaceutical and biotechnology companies from Australia, the Asia Pacific region, North America and Europe will also be attending.
Presenting companies will be a mix of listed companies in late-stage development, private companies with identified product/opportunities and early-stage commercialisation companies from research institutes and universities and include: CSL; Cochlear; ChemGenex; Starpharma; Biota Holdings; ResMed and Pharmaxis.
International investors confirmed include: ABN Ambro Morgans, Blueprint, CM Capital Investments, Baillieu Stockbroking, GBS Venture Partners, GlaxoSmithKline, Eli Lilly; 5AM Ventures; BioTech Healthcare Partners; SMH Capital; Amgen and Bailard.
For additional event information and a full list of confirmed attendees visit the Summit website at: http://www.ausbiotech2009.com.au/alsis/
